1163 results about "CD3" patented technology

The invention relates to an anti-CD3 nano antibody, an anti-CD38 antibody and a bispecific antibody containing the anti-CD3 nano antibody and the anti-CD38 antibody. According to the invention, an anti-CD3 nano antibody and an anti-CD38 monoclonal antibody are excavated and prepared, humanized design is carried out to obtain antibodies with high affinity and specificity, and different configurations of bispecific T cell conjugation antibodies targeting CD3 and CD38 are further designed, so that the CD3 and CD38 dual-specificity T cell conjugation antibodies are obtained. The antigen binding activity, the T cell-mediated tumor cell killing effect and the T cell proliferation and activation function of the antibody are systematically evaluated in vitro, and experimental results show that the T cell conjugation antibody can effectively recruit and activate T cells and has a remarkable killing effect on CD38 positive tumor cells, and it is further verified that the antibody has remarkable in-vivo anti-tumor activity and has a good application prospect. Therefore, the polypeptide has high affinity, good pharmacological characteristics and development potential.

Provided by the present invention are a bispecific T-cell engager, recombinant oncolytic virus thereof, and use thereof. The present invention provides an αCD47 and αCD3 bispecific T-cell engager. The present invention also provides an isolated nucleic acid molecule that encodes said bispecific T-cell engager. The present invention also provides an expression framework of said bispecific T-cell engager BiTE. The present invention also provides a recombinant oncolytic virus, and said oncolytic virus is operably inserted with or contains the expression framework of said bispecific T-cell engager BiTE. In the present invention, the bispecific T-cell engager is combined with the oncolytic virus, and in comparison with pure gene therapy or virotherapy, the oncolytic virus significantly enhances the inhibition capability on malignant tumors.

Disclosed are lipid nanoparticle (LNP) delivery systems that specifically target T cells. The LNP delivery system comprises antibodies conjugated to the surface of the LNP, e.g., via maleimide chemistry, that target at least two T cell surface proteins, e.g., CD3 and CD28. The LNP delivery system can have a single population of LNP conjugated to either a bispecific antiCD3 / antiCD28 antibody, or two monospecific antiCD3 and antiCD28 antibodies, or two populations of LNP wherein each population comprises a monospecific antibody. The payload of the LNP delivery system can be, e.g., mRNA encoding chimeric antigen receptors (CAR), a linear DNA fragment or a plasmid encoding chimeric antigen receptors (CAR) or therapeutic proteins such as antibodies, components of a gene editing systems (e.g., CRISPR-Cas), small molecules, antibody-drug conjugates (ADC), and any combination thereof, either encapsulated in the LNP or attached to its surface (e.g., conjugated). Also provided are lipids, pharmaceutical compositions, kits, and methods of treatment.

The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

The invention provides methods of dosing for the treatment of cancers, such as B cell proliferative disorders, with anti-cluster of differentiation 20 (CD20) / anti-cluster of differentiation 3 (CD3) bispecific antibodies.

The invention belongs to the technical field of tumor micro-immune environments, and particularly relates to a kit for detecting a tumor micro-environment, a detection method and application, the kit comprises rare metal element labeled monoclonal antibodies, the rare metal element labeled monoclonal antibodies comprise 115In-CD20, 139La-Histone H3, 142Nd-CD56, 144Nd-CD14, 146Nd-Vimentin, 148Nd-Pan-CK, 151Eu-CD31, 156Gd-CD4, 158Gd-E-Cadrin, 159Tb-CD68, 162Dy-CD8a, 166Er-CD45, 167Er-CD15, 170Er-CD3, 171Yb-CD11c and 209Bi-alpha-SMA, and the rare metal element labeled monoclonal antibodies comprise The invention can be used for simultaneously detecting and researching the quantity, positioning and spatial topological relation of each cell component in a tumor microenvironment, and provides a multi-immunofluorescence detection kit and method for ubiquitous epithelial differentiation-derived tumors based on an imaging mass spectrum flow technique. A plurality of biomarkers can be analyzed at the same time by using multiple immunohistochemical staining and rare earth metal tag signal detection technologies, so that the aim of performing high-dimensional analysis on a tumor microenvironment is fulfilled according to cell composition, functional state and cell-cell space interaction relationship.

The invention relates to a culture method for activating NKT cells by DC cells in vitro and application of the NKT cells. The preparation method of the NKT cell comprises the following steps: activating a DC cell by using cell inducing factors such as alpha-GalCer, GM-CSF and IL-4, co-culturing the DC cell and a cryopreserved and resuscitated suspension cell left after adherent sorting, and activating and amplifying the NKT cell. The proportion of NKT (CD3 + CD56 +) prepared by the invention is more than 80%, and a small amount of iNKT cells are contained at the same time.

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

Provided are a fusion protein (for example, in the form of a bispecific antibody) binding to CD235a and CD3, a preparation method therefor, and a related use thereof.

The present disclosure relates to a method for ameliorating or treating malignant ascites using an anti-EpCAM × CD3 bispecific antibody and a composition thereof and use of the anti-EpCAM × CD3 bispecific antibody and a composition thereof in ameliorating or treating malignant ascites. The present disclosure features better dosing convenience, longer dosing intervals, longer dosing cycles, and improved efficacy and safety.

A bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. A nucleic acid comprising a polynucleotide encoding the antibody construct, a vector comprising the nucleic acid comprising the polynucleotide and a host cell transformed or transfected with the nucleic acid comprising the polynucleotide or vector. A process for the production of the antibody construct, a medical use of the antibody construct in the treatment of melanoma, and a kit comprising the antibody construct.

An antibody capable of binding to LILRB4 and a bispecific antibody capable of binding to LILRB4 and CD3 are provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. Also provided are methods of treating solid tumors, multiple myeloma or leukemia, such as acute myelogenous leukemia (AML), using the anti-LILRB4xCD3 double antibodies of the present invention.

Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and / or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.

Provided are multispecific antigen binding proteins (MSAPs), such as trispecific antigen binding proteins (TSAPs or trispecific T cell engagers), that specifically bind to CD20, CD19, and CD3. Also provided are TSAPs or bispecific antigen binding proteins (BSAPs), that specifically bind to CD3 and CD20. Compositions (e.g., pharmaceutical compositions), kits, methods of use (e.g., treating cancer), and methods of making thereof are also provided.

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20 / anti-CD3 bispecific antibody (e.g., mosunetuzumab).

The invention belongs to the field of microorganisms and fermentation, and relates to a biological preparation, a preparation method thereof and application of the biological preparation in preparation of products for inhibiting escherichia coli. And the biological agent is a co-fermentation product of fructus forsythiae and bacillus amyloliquefaciens (Bacillus amyloliquefaciens). The biological preparation provided by the invention can obviously improve the secretion of IFN-alpha in a mouse body, reduce the production of IL-1beta, IL-6 and TNF-alpha, increase the proportion of CD3 + CD4 + and CD3 + CD8 + T cells, and improve the expression of ZO-1 and Occludin in duodenum and jejunum. Compared with single use of fructus forsythiae and bacillus amyloliquefaciens, the biological preparation shows a stronger synergistic effect, can effectively prevent and inhibit escherichia coli infection, and is not easy to generate drug resistance. The preparation method is simple, raw materials are easy to obtain, and the feed additive is suitable for developing antibacterial drugs and feed additives.

Provided is a chimeric antigen receptor targeting GCC, comprising: an scFv that specifically recognizes GCC, a CD8 hinge region or a CD28 hinge region, a CD8 transmembrane region or a CD28 transmembrane region, a CD28 co-stimulatory signal domain or a 4-1BB co-stimulatory signal domain, and a CD3ζ signal domain; the scFv that specifically recognizes GCC comprises a heavy chain variable region VH and a light chain variable region VL, the VH comprising an HC CDR1 having the amino acid sequence shown in SEQ ID NO: 1, an HC CDR2 having the amino acid sequence shown in SEQ ID NO: 2, and an HC CDR3 having the amino acid sequence shown in SEQ ID NO: 3, and the VL comprising an LC CDR1 having the amino acid sequence shown in SEQ ID NO: 4, an LC CDR2 having the amino acid sequence shown in SEQ ID NO: 5, and an LC CDR3 having the amino acid sequence shown in SEQ ID NO: 6.

Provided herein are novel Glypican 3 (GPC3) antibodies or antigen binding fragments and GPC3 / CD3 bispecific antibodies. The present application also provides chimeric antigen receptors comprising the antibodies or antigen-binding fragments, related CAR-T cells, and preparation methods and uses of the same. The present application further provides pharmaceutical compositions comprising GPC3 antibodies or antigen binding fragments, related GPC3 / CD3 bispecific antibodies, related GPC3 CAR or CAR-T cells, and methods of treating cancer in a subject in need thereof by administering the Glypican 3 (GPC3) antibodies or antigen binding fragments, the bispecific antibodies, the chimeric antigen receptors, the CAR-T cells, or the pharmaceutical compositions. The cancers treated in accordance with the application include Glypican-3-positive cancers.

The invention discloses an NKT cell culture optimization method, and belongs to the technical field of cell culture.The method comprises the steps that firstly, PBMC is sorted through a spiral micro-fluidic chip integrated with CD3 / CD56 double-labeled magnetic beads, and CD3 + CD56 + cells with the purity larger than or equal to 95% are obtained through the synergistic effect of dielectrophoretic force and a magnetic field; then, in a GIBCO culture solution added with the IL-2 / IL-15 / alpha-GalCer sustained release microspheres, the pH, dissolved oxygen and lactic acid concentration are accurately regulated and controlled through a real-time monitoring system, and temperature-oxygen partial pressure gradient culture is adopted; and finally, three times of centrifugation are combined with NKT4 solution treatment, and the cells are collected in cooperation with a gradient cooling procedure, so that the cell activity maintenance rate is greater than or equal to 95%. Compared with the traditional technology, the method has the advantages that the NKT cell sorting purity and activity are remarkably improved, the culture environment is regulated and optimized through dynamic metabolism, and accurate control over the culture process is achieved.

The invention discloses a fusion protein of a bispecific antibody targeting a T cell and Her2 in series connection with IL-15 and a receptor thereof and an application of the fusion protein. Belongs to the technical field of biology. The fusion protein disclosed by the invention can be combined with a recombinant human CD3 protein and a recombinant human Her2 protein, can be combined with NK92 and SK-BR-3 cell lines, can stimulate NK92 cell proliferation, and can respectively cause ADCC effects mediated by T and NK cells; the antibody has important economic and social significance.

To provide methods of treating a B-cell proliferative disorder.SOLUTION: The present invention relates to methods of treating a B-cell proliferative disorder by administering an anti-CD20 / anti-CD3 bispecific antibody, and methods for reduction of adverse effects in response to the administration of the anti-CD20 / anti-CD3 bispecific antibody. The present invention further relates to combination treatment methods of treating a B-cell proliferative disorder.SELECTED DRAWING: None

The present invention discloses CLDN18.2-targeting antibodies, bispecific antibodies and use thereof. The CLDN18.2-targeting antibody is a single-domain heavy-chain antibody that has high affinity for tumor cells endogenously expressing CLDN18.2 and can induce high endocytic activity. The bispecific antibody can target CLDN18.2 and CD3 and retains the binding effect of an Fc to an FcRn; meanwhile, a mutant Fc is preferred so as to reduce the binding to an FcgR and thus the activation of non-specific T cells caused by the cross-linking of an FcgR. The CD3-terminus activity is optimized so that the release of common cytokines in CRS, such as IL6 and TNFα can be reduced.

An antigen-binding molecule capable of binding to multiple different antigens (e.g., CD3 on T cells, and CD137 on T cells, NK cells, DC cells, and / or the like), but does not nonspecifically crosslink two or more immune cells such as T cells is provided. Such multispecific antigen-binding molecule is capable of modulating and / or activating an immune response while circumventing the cross-linking between different cells (e.g., different T cells) resulting from the binding of a conventional multispecific antigen-binding molecule to antigens expressed on the different cells, which is considered to be responsible for adverse reactions when the multispecific antigen-binding molecule is used as a drug.

The present disclosure describes low pH formulations comprising. e.g., an antigen-binding protein that binds CD3, at least one buffer agent, at least one saccharide and at least one surfactant.

The present invention relates to combination therapies employing tumor targeted anti-CEA / CD3 bispecific antibodies and / or agents blocking PD-L1 / PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules that also target FAP, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

The present invention relates to methods of treating prostate cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a KLK2xCD3 bispecific antibody or bispecific binding fragment thereof to the subject to treat the prostate cancer.

The invention relates to the technical field of biology, in particular to a tri-specific antibody based on structure optimization protein activity and application of the antibody. Specifically, the invention relates to a trispecific antibody specifically combined with Her2, CD3 and CD28, and the Her2 / CD3 / CD28 trispecific antibody comprises a Fab part of a monoclonal antibody specifically combined with CD3, an antibody fragment specifically combined with Her2 and an antibody fragment specifically recognized with CD28. The invention also relates to an application of the antibody in preparing a medicine for treating cancers, and the antibody plays an important role in treating human tumors.

The present invention provides dosing regimens of bispecific antibodies that target both CD3 and CD20 when used in the treatment of lymphoma, such as B cell non-Hodgkin lymphoma (B-NHL).

Disclosed herein are recombinant antibodies or antigen binding fragments thereof that comprise a tumor-associated calcium signal transducer 2 (TROP2) binding domain that has been optimized for binding and kinetic properties. In some embodiments, the recombinant antibodies or antigen binding fragments thereof further comprise a CD3 binding domain.